Oncternal Therapeutics (ONCT)
(Delayed Data from NSDQ)
$8.29 USD
+0.04 (0.48%)
Updated Apr 26, 2024 03:32 PM ET
After-Market: $8.21 -0.08 (-0.97%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Oncternal Therapeutics (ONCT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$30.67 | $39.00 | $25.00 | 271.76% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Oncternal Therapeutics comes to $30.67. The forecasts range from a low of $25.00 to a high of $39.00. The average price target represents an increase of 271.76% from the last closing price of $8.25.
Analyst Price Targets (3 )
Broker Rating
Oncternal Therapeutics currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 1.50 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, three are Strong Buy, representing 75% of all recommendations. A month ago, Strong Buy represented 75%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/15/2024 | H.C. Wainwright & Co. | Raghuram Selvaraju | Strong Buy | Strong Buy |
12/4/2023 | Brookline Capital Markets | Kemp Dolliver | Hold | Strong Buy |
11/10/2023 | Northland Capital Markets | Carl Byrnes | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.50 |
ABR (Last week) | 1.50 |
# of Recs in ABR | 4 |
Average Target Price | $30.67 |
LT Growth Rate | NA |
Industry | Medical - Drugs |
Industry Rank by ABR | 89 of 252 |
Current Quarter EPS Est: | -2.88 |